Skip to main content
HYUNDAI BIOLAND Co.,Ltd. logo

HYUNDAI BIOLAND Co.,Ltd. — Investor Relations & Filings

Ticker · 052260 ISIN · KR7052260007 KO Manufacturing
Open in API
Filings indexed 288 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 052260

About HYUNDAI BIOLAND Co.,Ltd.

https://www.hyundaibiolandmedical.com/

HYUNDAI BIOLAND Co., Ltd. is a comprehensive healthcare company specializing in the development and manufacturing of biomaterials from natural resources. The company's core business operates in three main sectors: cosmetic raw materials, health supplements (nutraceuticals), and biomedical materials for regenerative medicine. Leveraging expertise in collagen and hyaluronic acid manufacturing techniques, it provides high-tech bio-solutions for health and beauty. Its product portfolio includes active ingredients for the personal care industry, functional food materials, and medical devices such as resorbable membranes for dental and periodontal tissue regeneration. The company focuses on researching and supplying advanced biomaterials to a global market.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 91% confidence The document is a Korean “분기보고서” (quarterly report) for the 32nd fiscal period covering 2026-01-01 to 2026-03-31. It contains detailed narrative business overview, segment revenues, cost of materials, production capacity, and other substantive financial and operational data typical of a comprehensive interim/quarterly filing rather than a mere summary or announcement. Therefore, it should be classified as an Interim / Quarterly Report (IR). Q1 2026
2026-05-15 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Regulatory Filings
2026-04-30 Korean
결산실적공시예고
Report Publication Announcement Classification · 90% confidence The document is a brief notice announcing the scheduled publication date for the company’s quarterly financial results (Q1 2026). It does not contain actual financial data but only the date and scope of the upcoming results. This matches the definition of a Report Publication Announcement (RPA).
2026-04-27 Korean
배당락
Notice of Dividend Amount Classification · 85% confidence The document is a very brief notice (238 characters) detailing the ex-dividend date (배당락 실시일) for the company 현대바이오랜드. It does not present a full report but simply informs shareholders of the dividend-related event (ex-dividend date). This aligns with the Notice of Dividend Amount category.
2026-04-01 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (AGM). It contains specific details on voting outcomes for agenda items such as financial statement approval, dividend declarations, and the appointment of directors and audit committee members. This aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2026-03-20 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 90% confidence The document is a 'Corporate Value Enhancement Plan' (기업가치 제고 계획) filed by Hyundai Bioland. It outlines the company's future dividend policy, growth strategies, and profitability goals. In the context of Korean regulatory filings (DART), this type of voluntary disclosure regarding corporate value improvement does not fit into standard financial reporting categories like 10-K or IR, nor is it a simple announcement of a report. It is a specific regulatory disclosure regarding corporate governance and strategic planning, making 'Regulatory Filings' (RNS) the most appropriate fallback category.
2026-03-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.